Quanterix Announces Commercial Availability of New SR-X Ultra-Sensitive Biomarker Detection System™
Ultra-Sensitive Biomarker Detection System is now available in a compact size with increased workflow flexibility
"We are thrilled to be able to leverage the sensitivity of Simoa for key
low abundance biomarkers that we have been developing for Parkinson's
disease and other neurological disorders. The SR-X platform will enable
us to develop some critically informative multiplex panels that can
offer unprecedented sensitivity for early neurological disease
detection, monitoring, and exciting new therapeutic development," said
The SR-X is designed to support multiplexed detection of up to six biomarkers per sample, with low volume requirements, to increase throughput and productivity while conserving precious samples. A menu of Simoa assay kits are available to measure critical biomarkers with significantly higher sensitivity than standard, analog immunoassay methods, enabling detection of both normal and acute biomarker levels with high precision across a range of sample types.
“We are excited to see the rapid adoption of
The SR-X is for research use only and not for use in diagnostic procedures. For more information about the new SR-X Ultra-Sensitive Biomarker Detection System™, please visit: https://www.quanterix.com/srx.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to the potential ability of the SR-X platform to enable researchers to develop multiplex panels that can offer unprecedented sensitivity for early neurological disease detection, monitoring, and to enable new therapeutic development, and Simoa’s potential ability to change the way in which healthcare is provided today, and are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005507/en/
Source:
PAN Communications
Lauren Kaufman, 617-502-4300
quanterix@pancomm.com